FLT3 and acute myeloid leukemia: In a phase II studies of relapsed or refractory FLT3-mutated AML (NCT01522469, NCT01657682), crenolanib achieved composite remission rates of approximately 37–39% in FLT3-TKI-naive patients, with overall response rates approaching 50% [76,77].